Stocks-TNDM-Tandem Diabetes Care Inc

TNDM Tandem Diabetes Care Inc

38.76 -1.48 (-3.68%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Invest

Performance

0% Past Week
Market Cap
2.5B
Day’s Range
37.96
-
40.42
52W Range
33.46
-
123.83
Volume (3M)
1.27M
Price-Earnings Ratio
-26.3
Revenue
801.22M
Pinned Post
eToro Team
📰 EXTRA EXTRA…New charts arrived on eToro! Today we would like to give an official welcome to our new charts, in partnership with TradingView, one of the market leaders in charting and analysis tools. Yes, we know! You have already noticed the change but now we want to share with you what this complete... Show More
Like CommentShare
Show more comments2 of 102
2 replies
null
.
Top Discussions

About Tandem Diabetes Care Inc

Tandem Diabetes Care, Inc. is a US-based healthcare and biotechnology company that operates domestically. It specialises in supplying insulin pumps and glucose monitoring systems for children and adults who have insulin-dependent diabetic conditions. The company was founded in 2006 in San Diego, California, where its headquarters are located. It employs 1,500 people. Tandem Diabetes’ key product is the t:slim X2 Insulin Delivery System, which is as much as 38% smaller than its competitors. It can be used as a standalone device or in conjunction with the Dexcom G6 continuous glucose monitoring (CGM) system and features a large touchscreen and remote software update functionality. Other products in the Tandem Diabetes range include Basal-IQ technology and Control-IQ technology. Control IQ technology is designed to maximise the time a user stays within the target glycaemic range. Basal-IQ technology offers users a predictive suspend feature, whereby the delivery of insulin is suspended temporarily to minimise the risk of hypoglycaemic episodes. Tandem Diabetes Inc. trades on the NASDAQ using the ticker TNDM. The company works with a network of distribution partners in 21 countries, including Australia, Canada, South Africa, and the United Kingdom. Follow TNDM stock price changes and get the latest news on Tandem Diabetes with your eToro watchlist.
2.6K
Employees
San Diego, California, US
HQ
2006
Founded
John F. Sheridan, MBA
CEO
Show More

Upcoming Earnings

3
MAY
REPORTS
Tandem Diabetes Care Inc Q1 2023 earnings report is expected to be released after market open

Analyst Forecast

Consensus
Strong Buy
Price Target
54.60

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
53
Medium
Industry 
Avg. 51 
45
Environment
59
Social
51
Governance

People Also Bought